Syntegon reported sales of EUR883m for the first half of 2026, up 7% year-on-year, driven primarily by double-digit growth in its pharmaceutical business.
Adjusted EBITDA increased 16% to EUR148m, while the adjusted EBITDA margin reached 16.8%, an increase of 130 basis points compared with the first half of 2025. Order intake totaled EUR964m, with a book-to-bill ratio of 1.09 and a record order backlog of EUR1.3bn.
Torsten Türling, CEO of Syntegon, stated: “Our first-half 2026 results underline the positive impact of our strategy and the strength of Syntegon’s market position, […] Our Pharma business remains our strongest growth engine. We achieved major new customer wins and market share gains in the expanding biologics market globally and in the United States in particular.”
Syntegon’s Pharma sales increased 14% during the period, supported by demand for aseptic Fill & Finish and isolator-equipped line solutions, as well as continued investment in biologics and injectable medicines. The Pharma Solid business also recorded double-digit growth.
The company’s Food business faced more challenging market conditions during the first half, particularly in the Chocolate & Bars segment, where cost pressures resulted in more cautious investment decisions among customers.
Against this backdrop, Syntegon introduced new solutions aimed at improving production efficiency and flexibility. The company highlighted increasing customer adoption of its SVX vertical packaging platform and said it is taking measures to respond to current market conditions while maintaining its premium margin position.
During the first half, Syntegon also launched next-generation solutions incorporating increased automation, robotics and AI-enabled functionality. The developments are intended to address manufacturers’ demand for more automated, flexible and efficient production amid labor shortages, cost pressures, regulatory requirements and increasing portfolio complexity.
The CFO of Syntegon, Eros Carletti, said: “Our first-half results demonstrate Syntegon’s strong operating leverage. Adjusted EBITDA increased more than twice as fast as sales, taking the margin to 16.8%, […] This reflects the stronger earnings contribution from Pharma, operational discipline and continued improvements in project execution.”
Syntegon maintained its full-year 2026 outlook, expecting continued growth and margin expansion, supported by its order book, demand in the Pharma and Biotech businesses and a continued focus on operational execution.
